Jorge Chahla1, Nicolas S Piuzzi2, Justin J Mitchell3, Chase S Dean4, Cecilia Pascual-Garrido5, Robert F LaPrade6, George F Muschler7. 1. Steadman Philippon Research lnstitute, Vail, Colorado jchahla@sprivail.org. 2. Institute of Orthopedics, "Carlos E. Ottolenghi" Italian Hospital of Buenos Aires, Buenos Aires, Argentina nicolas.piuzzi@hospitalitaliano.org.ar. 3. Steadman Philippon Research lnstitute, Vail, Colorado jmitchell@thesteadmanclinic.com. 4. Steadman Philippon Research lnstitute, Vail, Colorado cdean@sprivail.org. 5. University of Colorado, Aurora, Colorado cecilia.pascualgarrido@gmail.com. 6. Steadman Philippon Research lnstitute, Vail, Colorado The Steadman Clinic, Vail, Colorado drlaprade@sprivail.org. 7. Department of Biomedical Engineering, Cleveland Clinic, Cleveland, Ohio muschlg@ccf.org.
Abstract
BACKGROUND: Intra-articular cellular therapy injections constitute an appealing strategy that may modify the intra-articular milieu or regenerate cartilage in the settings of osteoarthritis and focal cartilage defects. However, little consensus exists regarding the indications for cellular therapies, optimal cell sources, methods of preparation and delivery, or means by which outcomes should be reported. METHODS: We present a systematic review of the current literature regarding the safety and efficacy of cellular therapy delivered by intra-articular injection in the knee that provided a Level of Evidence of III or higher. A total of 420 papers were screened. Methodological quality was assessed using a modified Coleman methodology score. RESULTS: Only 6 studies (4 Level II and 2 Level III) met the criteria to be included in this review; 3 studies were on treatment of osteoarthritis and 3 were on treatment of focal cartilage defects. These included 4 randomized controlled studies without blinding, 1 prospective cohort study, and 1 retrospective therapeutic case-control study. The studies varied widely with respect to cell sources, cell characterization, adjuvant therapies, and assessment of outcomes. Outcome was reported in a total of 300 knees (124 in the osteoarthritis studies and 176 in the cartilage defect studies). Mean follow-up was 21.0 months (range, 12 to 36 months). All studies reported improved outcomes with intra-articular cellular therapy and no major adverse events. The mean modified Coleman methodology score was 59.1 ± 16 (range, 32 to 82). CONCLUSIONS: The studies of intra-articular cellular therapy injections for osteoarthritis and focal cartilage defects in the human knee suggested positive results with respect to clinical improvement and safety. However, the improvement was modest and a placebo effect cannot be disregarded. The overall quality of the literature was poor, and the methodological quality was fair, even among Level-II and III studies. Effective clinical assessment and optimization of injection therapies will demand greater attention to study methodology, including blinding; standardized quantitative methods for cell harvesting, processing, characterization, and delivery; and standardized reporting of clinical and structural outcomes. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
BACKGROUND:Intra-articular cellular therapy injections constitute an appealing strategy that may modify the intra-articular milieu or regenerate cartilage in the settings of osteoarthritis and focal cartilage defects. However, little consensus exists regarding the indications for cellular therapies, optimal cell sources, methods of preparation and delivery, or means by which outcomes should be reported. METHODS: We present a systematic review of the current literature regarding the safety and efficacy of cellular therapy delivered by intra-articular injection in the knee that provided a Level of Evidence of III or higher. A total of 420 papers were screened. Methodological quality was assessed using a modified Coleman methodology score. RESULTS: Only 6 studies (4 Level II and 2 Level III) met the criteria to be included in this review; 3 studies were on treatment of osteoarthritis and 3 were on treatment of focal cartilage defects. These included 4 randomized controlled studies without blinding, 1 prospective cohort study, and 1 retrospective therapeutic case-control study. The studies varied widely with respect to cell sources, cell characterization, adjuvant therapies, and assessment of outcomes. Outcome was reported in a total of 300 knees (124 in the osteoarthritis studies and 176 in the cartilage defect studies). Mean follow-up was 21.0 months (range, 12 to 36 months). All studies reported improved outcomes with intra-articular cellular therapy and no major adverse events. The mean modified Coleman methodology score was 59.1 ± 16 (range, 32 to 82). CONCLUSIONS: The studies of intra-articular cellular therapy injections for osteoarthritis and focal cartilage defects in the human knee suggested positive results with respect to clinical improvement and safety. However, the improvement was modest and a placebo effect cannot be disregarded. The overall quality of the literature was poor, and the methodological quality was fair, even among Level-II and III studies. Effective clinical assessment and optimization of injection therapies will demand greater attention to study methodology, including blinding; standardized quantitative methods for cell harvesting, processing, characterization, and delivery; and standardized reporting of clinical and structural outcomes. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
Authors: Muhammad Farooq Rai; Hua Pan; Huimin Yan; Linda J Sandell; Christine T N Pham; Samuel A Wickline Journal: Transl Res Date: 2019-07-10 Impact factor: 7.012
Authors: Venkata P Mantripragada; Nicolas S Piuzzi; Jaiben George; Wesley Bova; Mitchell Ng; Cynthia Boehm; George F Muschler Journal: Regen Med Date: 2019-07-19 Impact factor: 3.806
Authors: Iain R Murray; Jorge Chahla; Marc R Safran; Aaron J Krych; Daniel B F Saris; Arnold I Caplan; Robert F LaPrade Journal: J Bone Joint Surg Am Date: 2019-05-15 Impact factor: 5.284
Authors: Thomas E Patterson; Cynthia Boehm; Chizu Nakamoto; Richard Rozic; Esteban Walker; Nicolas S Piuzzi; George F Muschler Journal: J Bone Joint Surg Am Date: 2017-10-04 Impact factor: 5.284
Authors: V P Mantripragada; W A Bova; C Boehm; N S Piuzzi; N A Obuchowski; R J Midura; G F Muschler Journal: J Bone Joint Surg Am Date: 2018-10-17 Impact factor: 5.284
Authors: Ian A Jones; Ryan Togashi; Melissa L Wilson; Nathanael Heckmann; C Thomas Vangsness Journal: Nat Rev Rheumatol Date: 2019-02 Impact factor: 20.543